LEO LUZNIK to Leukemia, Myeloid, Acute
This is a "connection" page, showing publications LEO LUZNIK has written about Leukemia, Myeloid, Acute.
Connection Strength
4.248
-
CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia. Blood. 2024 09 12; 144(11):1168-1182.
Score: 0.629
-
Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia. J Clin Invest. 2022 11 01; 132(21).
Score: 0.552
-
How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide. Hematology Am Soc Hematol Educ Program. 2019 12 06; 2019(1):513-521.
Score: 0.452
-
How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide. Blood. 2019 11 21; 134(21):1802-1810.
Score: 0.450
-
Teaching a Young Dog New Tricks: Modifications to the Post-Transplantation Cyclophosphamide Haploidentical Transplantation Platform. Biol Blood Marrow Transplant. 2018 06; 24(6):1108-1110.
Score: 0.403
-
Alternative Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. Semin Hematol. 2015 Jul; 52(3):232-42.
Score: 0.326
-
Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity. Nat Cancer. 2024 Apr; 5(4):601-624.
Score: 0.151
-
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience. Clin Lymphoma Myeloma Leuk. 2022 04; 22(4):260-269.
Score: 0.128
-
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Blood Cancer Discov. 2021 Nov; 2(6):616-629.
Score: 0.128
-
Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia. Transplant Cell Ther. 2021 12; 27(12):1021.e1-1021.e5.
Score: 0.127
-
Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS. Leukemia. 2020 06; 34(6):1563-1576.
Score: 0.114
-
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat Med. 2019 04; 25(4):603-611.
Score: 0.108
-
Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. JCI Insight. 2018 11 02; 3(21).
Score: 0.105
-
Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia. Curr Drug Targets. 2017; 18(3):315-331.
Score: 0.092
-
Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide. Leukemia. 2016 10; 30(10):2102-2106.
Score: 0.088
-
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015 Aug 20; 126(8):1033-40.
Score: 0.083
-
HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2014 Mar; 20(3):314-8.
Score: 0.074
-
New treatment approaches in acute myeloid leukemia: review of recent clinical studies. Rev Recent Clin Trials. 2012 Aug; 7(3):224-37.
Score: 0.068
-
Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol Blood Marrow Transplant. 2011 Sep; 17(9):1404-9.
Score: 0.061
-
Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells. Blood. 2011 Jan 13; 117(2):608-17.
Score: 0.060
-
Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res. 2008 Sep; 32(9):1439-47.
Score: 0.050